BRIEF published on 03/20/2026 at 13:05, 3 months 12 days ago ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
BRIEF published on 03/20/2026 at 13:05, 3 months 12 days ago ReproNovo nomme Mark Altmeyer président du conseil d'administration Biopharmaceutique Direction ReproNovo Mark Altmeyer Fécondité
PRESS RELEASE published on 03/20/2026 at 13:00, 3 months 12 days ago REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRIEF published on 09/30/2025 at 07:05, 9 months 1 day ago ReproNovo Gains Approval for RPN-001 Clinical Trial in China Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
BRIEF published on 09/30/2025 at 07:05, 9 months 1 day ago ReproNovo obtient l'approbation pour l'essai clinique RPN-001 en Chine Essai Clinique ReproNovo RPN-001 Approbation De La Chine Médecine De La Reproduction
PRESS RELEASE published on 09/30/2025 at 07:00, 9 months 1 day ago ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China China Male Infertility Clinical Trial ReproNovo RPN-001
BRIEF published on 07/01/2025 at 07:05, 1 year ago ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S. Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
BRIEF published on 07/01/2025 at 07:05, 1 year ago ReproNovo lance un essai de phase 2 pour un médicament contre l'infertilité masculine aux États-Unis Essai De Phase 2 ReproNovo RPN-001 Infertilité Masculine Faible Taux De Testostérone
PRESS RELEASE published on 07/01/2025 at 07:00, 1 year ago REPRONOVO ANNOUNCES FIRST PARTICIPANT INCLUDED IN U.S. PHASE 2 TRIAL OF RPN-001 FOR MALE INFERTILITY ReproNovo announces first participant in U.S. Phase 2 trial of RPN-001 for male infertility, aiming to develop oral therapy for low testosterone men with impaired semen quality Male Infertility Phase 2 Trial ReproNovo RPN-001 Aromatase Inhibitor
BRIEF published on 05/21/2025 at 07:05, 1 year 1 month ago ReproNovo Secures $65 Million for Phase 2 Trials in Reproductive Health Innovation Clinical Trials Series A Financing Reproductive Health ReproNovo
Published on 07/01/2026 at 14:30, 1 hour 55 minutes ago AIAI Holdings' MediGuide Launches Digital Platform
Published on 07/01/2026 at 13:30, 2 hours 55 minutes ago Sidney Resources Corporation Appoints Former Idaho Governor C.L. "Butch" Otter as Chairman of the Board
Published on 07/01/2026 at 13:00, 3 hours 25 minutes ago Fox River Issues Shares Pursuant to Exploration Agreement in Connection with Impending Arrangement
Published on 07/01/2026 at 03:15, 13 hours 10 minutes ago GLG Life Tech Corporation Announces 2026 AGM Voting Results
Published on 07/01/2026 at 01:00, 15 hours 25 minutes ago Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Published on 07/01/2026 at 16:05, 19 minutes ago Wultra Raises €6.8 Million in Series A Funding to Accelerate Global Expansion of Post-Quantum Digital Identity Solutions
Published on 07/01/2026 at 16:00, 25 minutes ago Rentschler Biopharma appoints Dr. Torsten Woehr as Chief Executive Officer
Published on 07/01/2026 at 15:55, 29 minutes ago DJI Agriculture Elevates Precision Farming with Global Launch of Agras T55 and T100 Dual Battery Spraying System
Published on 07/01/2026 at 15:29, 55 minutes ago Edison issues report on SDCL Efficiency Income Trust (SEIT)
Published on 07/01/2026 at 09:54, 6 hours 30 minutes ago Juin 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 07/01/2026 at 08:45, 7 hours 40 minutes ago Air Liquide investit plus de 170 millions USD aux États-Unis pour soutenir l'ambition de SK hynix de bâtir un écosystème mondial de mémoires pour l’IA
Published on 07/01/2026 at 08:45, 7 hours 40 minutes ago Air Liquide invests over 170M USD in the U.S. to support SK hynix’s ambition to build a global AI memory ecosystem
Published on 07/01/2026 at 07:00, 9 hours 25 minutes ago BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK
Published on 07/01/2026 at 07:00, 9 hours 25 minutes ago Biophytis communique ses résultats financiers provisoires et partage ses perspectives stratégiques
